Lachlan MacKinnon (L) and Adrian Woolfson (Replay)

Un­der hub-and-spoke biotech, se­r­i­al founders launch new start­up hop­ing to make gene ther­a­pies for the eye

In late Ju­ly, Sang­amo’s for­mer R&D chief Adri­an Woolf­son, who left the biotech when it split its R&D, launched his own gene ther­a­py out­fit. Re­play’s pri­ma­ry plat­form was an HSV vec­tor which, as a hub-and-spoke biotech, it said it was build­ing four dif­fer­ent com­pa­nies around.

Now, the first of those four com­pa­nies is out of the bag, with a co-found­ing team of four aca­d­e­mics who have deep biotech ex­pe­ri­ence. Named Eu­do­ra, the Re­play spoke com­pa­ny will go af­ter three eye dis­eases: re­tini­tis pig­men­tosa, Star­gardt dis­ease, and Ush­er syn­drome type 1B.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.